Market Closed - Xetra 16:35:01 03/05/2024 BST 5-day change 1st Jan Change
42.5 EUR -0.82% Intraday chart for Stratec SE +2.04% -6.70%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
STRATEC BIOMEDICAL SYSTEMS AG : Deutsche Bank reiterates its Neutral rating ZD
STRATEC BIOMEDICAL SYSTEMS AG : Berenberg reiterates its Neutral rating ZD
STRATEC BIOMEDICAL SYSTEMS AG : Warburg Research remains Neutral ZD
Stratec sees revival in second quarter - share price jumps DP
Stratec SE Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Weak start to the year for Stratec - recovery expected in the second quarter DP
STRATEC BIOMEDICAL SYSTEMS AG : Berenberg reiterates its Neutral rating ZD
STRATEC BIOMEDICAL SYSTEMS AG : Warburg Research remains Neutral ZD
STRATEC BIOMEDICAL SYSTEMS AG : DZ Bank reiterates its Neutral rating ZD
STRATEC BIOMEDICAL SYSTEMS AG : Deutsche Bank sticks Neutral ZD
STRATEC BIOMEDICAL SYSTEMS AG : Hauck & Aufhauser remains Neutral ZD
Stratec remains under pressure - LBBW: Predictability limited DP
STRATEC BIOMEDICAL SYSTEMS AG : Deutsche Bank remains Neutral ZD
Transcript : Stratec SE, 2023 Earnings Call, Mar 28, 2024
Stratec SE Reports Earnings Results for the Full Year Ended December 31, 2023 CI
STRATEC BIOMEDICAL SYSTEMS AG : Gets a Neutral rating from Warburg Research ZD
Berenberg rates Stratec at 'Hold' - Target 43 euros DP
STRATEC BIOMEDICAL SYSTEMS AG : Berenberg sticks Neutral ZD
Stratec development disappoints - Significant minus also for 2024 DP
Stratec continues to struggle with customer destocking - share price falls DP
Stratec continues to struggle with inventory reduction at customers - hopes for improvement DP
STRATEC BIOMEDICAL SYSTEMS AG : Deutsche Bank gives a Neutral rating ZD
Diagnostics specialist Stratec significantly reduces dividend DP
Stratec SE Proposes Dividend for Financial Year 2023 CI
Hauck Aufhäuser IB lowers Stratec to 'Hold' - target 40 euros DP
Chart Stratec SE
More charts
Stratec SE is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of in-vitro diagnostics and life sciences in Germany and internationally. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
42.5 EUR
Average target price
43.83 EUR
Spread / Average Target
+3.14%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. SBS Stock
  4. News Stratec SE
  5. German Medtech Company Stratec Jumps 19% on Takeover Interest from EQT, KKR